<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03051698</url>
  </required_header>
  <id_info>
    <org_study_id>2015_024</org_study_id>
    <nct_id>NCT03051698</nct_id>
  </id_info>
  <brief_title>C1-inhibitor in Allergic ASThma Patients</brief_title>
  <acronym>CAST</acronym>
  <official_title>Effect of Intravenous Administration of C1-inhibitor on Inflammation and Coagulation After Bronchial Instillation of House Dust Mite Allergen and Lipopolysaccharide in Allergic Asthma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>T. van der Poll</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanquin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this proof-of-concept study is to determine the effect of Intestinal
      Microbiota Depletion or Intravenous Administration of C1-inhibitor on Inflammation and
      Coagulation after Bronchial Instillation of House Dust Mite Allergen and Lipopolysaccharide
      in Allergic Asthma Patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravenous administration of C1-inhibitor (n=20) or vehicle (n=20). One group of patients
      (n=20) will receive broad spectrum antibiotics (vancomycin, ciprofloxacin, metronidazole) for
      7 days (washout 36 hours before study day). This group will receive the same vehicle as the
      control group 2 hours prior to challenge. HDM will be administered together with the
      environmental pollutant LPS in a lung subsegment via a bronchoscope (mimicking environmental
      exposure to HDM); a contralateral lung subsegment will be administered with saline (control
      side). After 7 hours, bronchoalveolar lavage (BAL) fluid will be harvested by a second
      bronchoscopy. Blood samples will be collected before administration of C1-inhibitor or
      vehicle, and before both bronchoscopies. Faeces will be collected prior to antibiotic
      administration as well as prior to HDM+LPS challenge.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2016</start_date>
  <completion_date type="Anticipated">November 16, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 16, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Influx of inflammatory cells in the lung</measure>
    <time_frame>7 hours after bronchial instillation of house dust mite (HDM) and lipopolyssacharide(LPS)</time_frame>
    <description>Most important cell types are the eosinophils and neutrophils in bronchoaveolar fluid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin-4 in pg/ml.</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-5 in pg/ml.</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-13 in pg/ml.</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-10 in pg/ml.</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IFN-Y in pg/ml.</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-α in pg/ml.</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCL11 in pg/ml.</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6 in pg/ml.</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C4bc u/ml</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C3bc u/ml</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iC3b u/ml</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C5a ng/ml</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C5b-9 u/ml.</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C3a in ng/ml</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FXIIa activity in OD</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FXIa in OD</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FXIIa- C1-inhibitor complexes u/ml</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kallikrein-C1-inhibitor complexes u/ml</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high-molecular weight kininogen in AU</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thrombin-antithrombin complexes in ng/ml.</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>C1-inhibitor activity in bronchoalveolar lavage</measure>
    <time_frame>7 hours after bronchial instillation of HDM and LPS</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>C1-inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One gift of intravenous administration of C1-inhibitor (Cinryze, 100U/kg) during one hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One gift of intravenous administration of 0.9% NaCl during one hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>broad spectrum antibiotics (vancomycin, ciprofloxacin, metronidazole) for 7 days (washout 36 hours before study day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C1-inhibitor</intervention_name>
    <description>100 Unit/kg IV, one gift prior to broncho provocation.</description>
    <arm_group_label>C1-inhibitor</arm_group_label>
    <other_name>Cinryze</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>0.9% NaCl</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotics</intervention_name>
    <description>vancomycin, ciprofloxacin, metronidazole</description>
    <arm_group_label>Antibiotics</arm_group_label>
    <other_name>vancomycin, ciprofloxacin, metronidazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intermittent to mild asthma according to the Global Initiative for Asthma (GINA)
             criteria

          -  Allergy for HDM documented by a positive RAST and a positive skin prick test.

          -  No clinically significant findings during physical examination and hematological and
             biochemical screening

          -  At spirometry FEV1 more than 70% of predicted value

          -  A PC20 between 0.3 - 9.6 mg/ml (corresponding with increased airway hyperreactivity)

          -  Able to communicate well with the investigator and to comply with the requirements of
             the study

          -  Stable asthma without the use of asthma medication 2 weeks prior to the study day. As
             documented by the Juniper's Asthma control questionnaire (ACQ) score &lt; 1,2.

          -  Written informed consent

          -  No current smoking for at least 1 year and less than 10 pack years of smoking history

        Exclusion Criteria:

          -  Relevant comorbidity, pregnancy and/or recent surgical procedures.

          -  A history of smoking within the last 12 months, or regular consumption of greater than
             three units of alcohol per day

          -  Exacerbation and/ or the use of asthma medication within 2 weeks before start

          -  Administration of any investigational drug within 30 days of study initiation

          -  Donation of blood within 60 days, or loss of greater than 400 ml of blood within 12
             weeks of study initiation]

          -  History of venous or arterial thromboembolic disease

          -  History of enhanced bleeding tendency or abnormal clotting test results.

          -  History of serious drug-related reactions, including hypersensitivity

          -  Inability to maintain stable without the use of asthma medication 2 weeks before start
             of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom vd Poll, Prof, dr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jack Yang, MD</last_name>
    <phone>+31205665247</phone>
    <email>j.yang@amc.uva.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom van der Poll, Prof.</last_name>
      <email>t.vanderpoll@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Jack Yang, MD</last_name>
      <email>j.yang@amc.uva.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Tom van der Poll, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Zeerleder S. C1-inhibitor: more than a serine protease inhibitor. Semin Thromb Hemost. 2011 Jun;37(4):362-74. doi: 10.1055/s-0031-1276585. Epub 2011 Jul 30. Review.</citation>
    <PMID>21805442</PMID>
  </reference>
  <reference>
    <citation>Zhang X, Köhl J. A complex role for complement in allergic asthma. Expert Rev Clin Immunol. 2010 Mar;6(2):269-77. Review.</citation>
    <PMID>20402389</PMID>
  </reference>
  <reference>
    <citation>Schmudde I, Laumonnier Y, Köhl J. Anaphylatoxins coordinate innate and adaptive immune responses in allergic asthma. Semin Immunol. 2013 Feb;25(1):2-11. doi: 10.1016/j.smim.2013.04.009. Epub 2013 May 19. Review.</citation>
    <PMID>23694705</PMID>
  </reference>
  <reference>
    <citation>de Boer JD, Berger M, Majoor CJ, Kager LM, Meijers JC, Terpstra S, Nieuwland R, Boing AN, Lutter R, Wouters D, van Mierlo GJ, Zeerleder SS, Bel EH, van't Veer C, de Vos AF, van der Zee JS, van der Poll T. Activated protein C inhibits neutrophil migration in allergic asthma: a randomised trial. Eur Respir J. 2015 Dec;46(6):1636-44. doi: 10.1183/13993003.00459-2015. Epub 2015 Sep 17.</citation>
    <PMID>26381519</PMID>
  </reference>
  <reference>
    <citation>Bel EH. Mild asthma. N Engl J Med. 2013 Dec 12;369(24):2362. doi: 10.1056/NEJMc1313111.</citation>
    <PMID>24328483</PMID>
  </reference>
  <reference>
    <citation>Krug N, Tschernig T, Erpenbeck VJ, Hohlfeld JM, Köhl J. Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1841-3.</citation>
    <PMID>11734433</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2017</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>T. van der Poll</investigator_full_name>
    <investigator_title>Prof. dr.</investigator_title>
  </responsible_party>
  <keyword>C1-inhibitor</keyword>
  <keyword>house dust mite</keyword>
  <keyword>complement system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

